Pre-Made Verpasep Caltespen biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HspE7(Mycobacterium bovis HSP65-HBV E7) fused with chaperonin 2 (HSP65 from Mycobacterium bovis) for drug discovery and mechanism of action (MOA) research

Pre-Made Verpasep Caltespen biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HspE7(Mycobacterium bovis HSP65-HBV E7) fused with chaperonin 2 (HSP65 from Mycobacterium bovis) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

HspE7 is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. It is being developed by StressGen Biotechnologies Corp. HspE7 works by efficiently delivering the E7 antigen to dendritic cells, which have a natural affinity for Hsp. Dendritic cells are known to be the most potent cells in the body for triggering immune responses. Coupling E7 to Hsp takes advantage of the Hsp receptors that dendritic cells express on their surface to introduce E7, as part of a larger fusion protein, into the dendritic cells.

Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1048-1mg	1mg	3090
GMP-Bios-INN-1048-10mg	10mg	Inquiry
GMP-Bios-INN-1048-100mg	100mg	Inquiry
GMP-Bios-INN-1048-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Verpasep Caltespen biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HspE7(Mycobacterium bovis HSP65-HBV E7) fused with chaperonin 2 (HSP65 from Mycobacterium bovis)
INN Name	Verpasep Caltespen
Target	HspE7(Mycobacterium bovis HSP65-HBV E7)
Format	Fusion Protein
Derivation	Mycobacterium tuberculosis variant bovis Alphapapillomavirus 9
Species Reactivity	human
CH1 Isotype	Fusion - Mycobacterium tuberculosis variant bovis chaperonin 2 (HSP65 from Mycobacterium bovis) - Alphapapillomavirus 9 E7 HPV16
VD LC	Fusion - Mycobacterium tuberculosis variant bovis chaperonin 2 (HSP65 from Mycobacterium bovis) - Alphapapillomavirus 9 E7 HPV16
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Nventa Biopharmaceuticals Corporation
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0